M-atrial natriuretic peptide: A novel antihypertensive protein therapy

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The natriuretic peptides, specifically atrial natriuretic peptide (ANP), are increasingly recognized to play a fundamental role in blood pressure (BP) regulation. This role in BP regulation reflects the pluripotent cardiorenal actions of ANP, which include diuresis, enhancement of renal blood flow and glomerular filtration rate, systemic vasodilatation, suppression of aldosterone, and inhibition of the sympathetic nervous system. These actions of ANP, in addition to recent human studies demonstrating an association of higher plasma ANP with lower risk of hypertension, support the development of an ANP-based therapy for hypertension. M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function-enhancing, and aldosterone-suppressing properties than native ANP. In an animal model of hypertension, M-ANP lowers BP via multiple mechanisms, including vasodilatation, diuresis, and inhibition of aldosterone. Importantly, M-ANP enhances both glomerular filtration rate and renal blood flow despite reductions in BP. The pluripotent BP-lowering actions and concomitant enhancement of renal function associated with M-ANP are highly attractive characteristics for an antihypertensive agent and underscore the therapeutic potential of M-ANP. M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension.

Original languageEnglish (US)
Pages (from-to)62-69
Number of pages8
JournalCurrent Hypertension Reports
Volume14
Issue number1
DOIs
StatePublished - Feb 2012

Fingerprint

Atrial Natriuretic Factor
Antihypertensive Agents
Proteins
Blood Pressure
Therapeutics
Aldosterone
Hypertension
Renal Circulation
Diuresis
Glomerular Filtration Rate
Vasodilation
peptide A
Kidney
Natriuretic Peptides
Sympathetic Nervous System
Animal Models

Keywords

  • Atrial natriuretic peptide
  • Blood pressure
  • Cyclic guanosine monophosphate
  • Heart failure
  • Hypertension
  • M-ANP
  • Natriuretic peptide
  • Renal function
  • Therapeutics
  • Treatment

ASJC Scopus subject areas

  • Internal Medicine

Cite this

M-atrial natriuretic peptide : A novel antihypertensive protein therapy. / McKie, Paul; Ichiki, Tomoko; Burnett, John C Jr.

In: Current Hypertension Reports, Vol. 14, No. 1, 02.2012, p. 62-69.

Research output: Contribution to journalArticle

@article{c3e85c3dffe449d1a998e7af66242af9,
title = "M-atrial natriuretic peptide: A novel antihypertensive protein therapy",
abstract = "The natriuretic peptides, specifically atrial natriuretic peptide (ANP), are increasingly recognized to play a fundamental role in blood pressure (BP) regulation. This role in BP regulation reflects the pluripotent cardiorenal actions of ANP, which include diuresis, enhancement of renal blood flow and glomerular filtration rate, systemic vasodilatation, suppression of aldosterone, and inhibition of the sympathetic nervous system. These actions of ANP, in addition to recent human studies demonstrating an association of higher plasma ANP with lower risk of hypertension, support the development of an ANP-based therapy for hypertension. M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function-enhancing, and aldosterone-suppressing properties than native ANP. In an animal model of hypertension, M-ANP lowers BP via multiple mechanisms, including vasodilatation, diuresis, and inhibition of aldosterone. Importantly, M-ANP enhances both glomerular filtration rate and renal blood flow despite reductions in BP. The pluripotent BP-lowering actions and concomitant enhancement of renal function associated with M-ANP are highly attractive characteristics for an antihypertensive agent and underscore the therapeutic potential of M-ANP. M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension.",
keywords = "Atrial natriuretic peptide, Blood pressure, Cyclic guanosine monophosphate, Heart failure, Hypertension, M-ANP, Natriuretic peptide, Renal function, Therapeutics, Treatment",
author = "Paul McKie and Tomoko Ichiki and Burnett, {John C Jr.}",
year = "2012",
month = "2",
doi = "10.1007/s11906-011-0244-5",
language = "English (US)",
volume = "14",
pages = "62--69",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - M-atrial natriuretic peptide

T2 - A novel antihypertensive protein therapy

AU - McKie, Paul

AU - Ichiki, Tomoko

AU - Burnett, John C Jr.

PY - 2012/2

Y1 - 2012/2

N2 - The natriuretic peptides, specifically atrial natriuretic peptide (ANP), are increasingly recognized to play a fundamental role in blood pressure (BP) regulation. This role in BP regulation reflects the pluripotent cardiorenal actions of ANP, which include diuresis, enhancement of renal blood flow and glomerular filtration rate, systemic vasodilatation, suppression of aldosterone, and inhibition of the sympathetic nervous system. These actions of ANP, in addition to recent human studies demonstrating an association of higher plasma ANP with lower risk of hypertension, support the development of an ANP-based therapy for hypertension. M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function-enhancing, and aldosterone-suppressing properties than native ANP. In an animal model of hypertension, M-ANP lowers BP via multiple mechanisms, including vasodilatation, diuresis, and inhibition of aldosterone. Importantly, M-ANP enhances both glomerular filtration rate and renal blood flow despite reductions in BP. The pluripotent BP-lowering actions and concomitant enhancement of renal function associated with M-ANP are highly attractive characteristics for an antihypertensive agent and underscore the therapeutic potential of M-ANP. M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension.

AB - The natriuretic peptides, specifically atrial natriuretic peptide (ANP), are increasingly recognized to play a fundamental role in blood pressure (BP) regulation. This role in BP regulation reflects the pluripotent cardiorenal actions of ANP, which include diuresis, enhancement of renal blood flow and glomerular filtration rate, systemic vasodilatation, suppression of aldosterone, and inhibition of the sympathetic nervous system. These actions of ANP, in addition to recent human studies demonstrating an association of higher plasma ANP with lower risk of hypertension, support the development of an ANP-based therapy for hypertension. M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function-enhancing, and aldosterone-suppressing properties than native ANP. In an animal model of hypertension, M-ANP lowers BP via multiple mechanisms, including vasodilatation, diuresis, and inhibition of aldosterone. Importantly, M-ANP enhances both glomerular filtration rate and renal blood flow despite reductions in BP. The pluripotent BP-lowering actions and concomitant enhancement of renal function associated with M-ANP are highly attractive characteristics for an antihypertensive agent and underscore the therapeutic potential of M-ANP. M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension.

KW - Atrial natriuretic peptide

KW - Blood pressure

KW - Cyclic guanosine monophosphate

KW - Heart failure

KW - Hypertension

KW - M-ANP

KW - Natriuretic peptide

KW - Renal function

KW - Therapeutics

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84857636992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857636992&partnerID=8YFLogxK

U2 - 10.1007/s11906-011-0244-5

DO - 10.1007/s11906-011-0244-5

M3 - Article

C2 - 22135207

AN - SCOPUS:84857636992

VL - 14

SP - 62

EP - 69

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 1

ER -